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Purpose: Previous studies have documented poor patency rates in “young” patients (age 55 years or younger) with
premature atherosclerosis undergoing aortofemoral bypass (AFB) to treat aortoiliac occlusive disease. Given the high
reported graft patency rates with superficial femoral vein (SFV) grafts performed because of aortic graft infection, we
evaluated the role of SFV grafts for AFB as primary therapy for premature atherosclerosis in a case-control study.
Methods: Over 10 years 31 patients aged 55 year or younger underwent AFB with use of SFV (V-AFB). Case controls
consisted of all patients 55 years of age or younger who underwent AFB with use of Dacron (D-AFB) during the same
period (n 80). In all cases this was the initial therapy (no repeat operations). The two groups were well matched for age,
sex, weight, preoperative ankle-brachial index, and the comorbid conditions of smoking, coronary artery disease, chronic
obstructive pulmonary disease, hyperlipidemia, hypertension, and renal insufficiency. There were more patients with
diabetes in the V-AFB group (34% vs 16%; P  .05). Patients in the V-AFB group had more advanced disease, and the
surgical indication was more frequently critical ischemia compared with the D-AFB group (90% vs 46%; P < .001).
Results: There was only one perioperative death in each group. There were no differences in cardiac, pulmonary, or
gastrointestinal complications. However, fasciotomy occurred more frequently with V-AFB (44% vs 1%; P < .001).
Surgery time was longer with V-AFB (7.3 vs 4.5 hours; P < .001). Despite these short-term drawbacks, V-AFB proved
superior at long-term follow-up. The 5-year primary patency rate was significantly higher with V-AFB than with D-AFB
(100% vs 56%; P  .013). There was also a trend for higher limb salvage at 5 years (90% vs 62%). Four graft infections
occurred with D-AFB, and none with V-AFB (P  .32).
Conclusions: AFB performed with SFV grafts is a far more durable operation than standard D-AFB in young patients with
aortoiliac occlusive disease. However, V-AFB is far more likely to require lower extremity fasciotomy, and takes almost
twice as long to perform. (J Vasc Surg 2004;40:17-23.)Although aortofemoral bypass (AFB) grafting with
prosthetic material has long been considered the standard
for treatment of severe aortoiliac occlusive disease, recent
studies have shown that when performed in patients with
premature atherosclerosis the results are not so good, with
5-year patency rates as low as 50%.1-3 Encouraged by the
excellent patency rates observed with the superficial femo-
ropopliteal vein (SFP) as graft material for aortic recon-
struction in patients with prosthetic infection,4 we used this
vein to construct AFB grafts in 31 patients 55 years old and
younger with aortoiliac occlusive disease. The purpose of
the study was to describe the technique and results of SFP
as a graft material for AFB in young patients with aortoiliac
occlusive disease. We also compared the results of this
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doi:10.1016/j.jvs.2004.04.002procedure with those in a control group of young patients
who underwent conventional AFB with prosthetic grafts.
The hypothesis was that primary patency is superior with
AFB grafts constructed from SFP vein compared with
conventional Dacron grafts.
METHODS
Data for all patients 55 years old and younger who
underwent AFB to treat aortoiliac occlusive disease be-
tween 1992 and 2003 were reviewed. These were all pri-
mary operations and not revisions of previous aortic oper-
ations. Clinical data were obtained from charts and a
computerized registry of operative cases. Patients receiving
SFP vein grafts were selected solely on the basis of surgeon
preference and were not randomly allocated. During the
study period seven attending vascular surgeons performed
the procedures.
Follow-up examinations were conducted within 1
month of surgery, at 6-month intervals for the first year,
and then annually. Graft patency was confirmed by the
presence of a palpable femoral pulse and by vascular labo-
ratory testing. Return of symptoms or significant changes
in results of vascular laboratory tests prompted additional
evaluation with angiography or operative intervention.17
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preoperatively with duplex ultrasound scanning to confirm
patency and suitable vein diameter. SFP vein diameter was
recorded proximally near the common femoral vein, in the
middle of the superficial femoral vein, and at the popliteal
vein. Areas of duplication or thrombotic segments were
noted. At surgery the SFP vein was initially exposed bilat-
erally from its origin at the common femoral vein to the
knee joint with an incision paralleling the lateral border of
the sartorius muscle. The vein was left in situ, with only the
branches ligated, until the vein was needed to construct the
bypass. After exposing the common femoral arteries and
the aorta transperitoneally, the SFP vein was divided and
harvested. Care was taken to ligate the SFP vein flush with
the common femoral vein, with layered vascular closure of
the vein to avoid a “stump” that could serve as a nidus for
thrombus formation. The SFP vein grafts were placed in the
non-reversed configuration to provide a better size match
with the aorta and common femoral arteries. The SFP vein
valves were lysed with a Mills-Leather type of valvulotome.
More recently we have abandoned the use of the valvu-
lotome and have instead inverted the vein graft and indi-
vidually excised each valve. Extended follow-up of patients
with SFP vein grafts created to treat aortic prosthetic infec-
tion showed a number of recurrent stenoses due to incom-
plete valve lysis.
Fig 1. Configuration of V-AFB grafts. Single vein proximal end-
to-side, n  13. Single vein proximal end-to-end, n  12.The proximal anastomosis was created either end-to-
end or end-to-side, at the discretion of the surgeon. End-
to-end anastomoses were created with one SFP vein to the
aorta in most cases, and with a pantaloon of both SFP veins
only if the vein diameter was too small for a single vein
proximal anastomosis. For cases with a single vein for the
proximal anastomosis the other vein was anastomosed end-
to-side to the first vein several centimeters distal to the
aortic anastomosis in a manner to facilitate tunneling and
orientation to the opposite common femoral artery.
Patients undergoing prosthetic AFB were selected at
the discretion of the attending vascular surgeon, again
without specific criteria to differentiate them from the SFP
vein group. The AFB bypass was constructed with Dacron
grafts, with limb sizes matched to the recipient common
femoral artery diameter. The diameter of the Dacron graft
limb was 8 mm in 65%, 7 mm in 18%, and 9 mm in 17%.
The type of proximal anastomosis, end-to-end or end-to-
side, was selected at the discretion of the attending sur-
geon.
Primary patency and limb salvage were defined accord-
ing to Society for Vascular Surgery recommended report-
ing standards.5 Surgery time was defined as from the initial
skin incision to placement of dressings. Patency rates, pa-
tient survival, and limb salvage were described with stan-
dard life tables. The two treatment groups were compared
Fig 2. Configuration of V-AFB grafts. Pantaloon veins proximal
end-to-end, n  3. Pantaloon veins proximal end-to-side, n  1.
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mean (normally distributed) or median (not normally dis-
tributed) with SD. Differences of means between the two
groups were compared with t tests. Categorical values were
compared with the 2 test or the Fisher exact test, as
appropriate. Significance of differences between groups was
determined at P  .05.
RESULTS
During the study 80 patients aged 55 years and
younger (range, 37-55 years) underwent AFB with Dacron
graft (D-AFB) and 31 received an AFB constructed with
SFP vein (V-AFB). Graft configuration for the V-AFB
group was as follows: single vein end-to-side proximal,
end-to-side contralateral femoral limb (n 13); single vein
end-to-end proximal, end-to-side contralateral femoral
limb (n  12); end-to-end proximal pantaloon (n  3);
end-to-end proximal with femorofemoral contralateral
limb (n  2); and end-to-side proximal pantaloon (n  1;
Figs 1 and 2).
The two groups were well matched for age, sex, weight,
and comorbid conditions other than diabetes, which was
more prevalent in the V-AFB group (Table I). A significant
difference between groups was the operative indication,
where critical ischemia (rest pain or tissue loss) was present
in 90% of the V-AFB group but in only 46% of the D-AFB
group (P  .001). The preoperative ankle-brachial index
was lower in the V-AFB group, but failed to reach statistical
significance (Table II). The V-AFB procedure took longer
to perform than the D-AFB (7.3  3.2 hours vs 4.5  1.0
hours; P  .001).
The median number of days spent in the intensive care
unit postoperatively was similar in both groups (V-AFB,
4.0 39 days, vs D-AFB, 3.0 2.6 days; P .22), and the
percentage of patients requiring more than 5 postoperative
days in the intensive care unit was the same in the V-AFB
and D-AFB groups (13.3% vs 12.5%). The total number of
hospital days was similar in both groups as well (V-AFB, 10
 17 days, vs D-AFB, 9  7.6 days; P  .33).
The incidence of postoperative complications was sim-
ilar in the two groups, with the exception of lower extrem-
ity fasciotomy, which was performed in 44% of the V-AFB
procedures and in only one (1.3%) of the D-AFB proce-
dures (P  .001; Table III). Fasciotomy was performed
prophylactically in most patients on the basis of subjective
assessment of calf muscle compartment tension at the end
of the procedure. Death within 30 days occurred in only
one patient in each group (P .51). Graft infection, which
is eliminated with the use of V-AFB, occurred in four
patients in the D-AFB group, but this was not statistically
significant (P  .32).
Mean follow-up was similar in both groups (V-AFB,
21.4  24 months, vs D-AFB, 24.1  25 months; P 
.62). Primary graft patency was significantly better in the
V-AFB group, inasmuch as none of the grafts occluded or
required revision (Table IV; Fig 3). In contrast, primary
patency with D-AFB was only 55.7% at 5 years (P .013).
There was a nonsignificant trend toward improved 5-yearlimb salvage with V-AFB (90%) compared with D-AFB
(62%; P  .35). Overall patient survival at 5 years was
numerically slightly higher with D-AFB (85%, 95% confi-
dence interval [CI], 76%-94%, vs 63%, 95% CI, 33%-93%),
but failed to reach statistical significance. Six patients in the
D-AFB group subsequently underwent conversion to V-
AFB, because of graft infection in four patients and occlu-
sive failure of the Dacron graft in two patients.
DISCUSSION
The most significant findings of this study are that AFB
grafting with SFP vein can be performed in young patients
as a primary means of aortic reconstruction with safety and
good short-term results, and there is an overwhelming
patency advantage with the use of SFP vein over the con-
Table 1. Patient demographic data and comorbid
conditions
D-AFB V-AFB P
No. of patients 80 31 —
Male gender (%) 60 72 .42
Mean age (y) 48.3 49.7 .18
Mean weight (lb) 166 163 .77
Smoker (%) 98 97 .50
Atherosclerotic heart disease (%) 29 29 1.00
Chronic obstructive pulmonary
disease (%)
10 11 1.00
Hyperlipidemia (%) 31 44 .24
Hypertension (%) 57 78 .06
Diabetes (%) 16 37 .03
D-AFB, Dacron aortofemoral bypass; V-AFB, vein aortofemoral bypass.
Table II. Degree of ischemia
D-AFB V-AFB P
Critical ischemia (%) 46 90 .001
Ankle-brachial index
Right leg 0.44 0.37 .44
Left leg 0.50 0.38 .16
D-AFB, Dacron aortofemoral bypass; V-AFB, vein aortofemoral bypass.
Table III. Resource usage and postoperative
complications
D-AFB V-AFB P
Operative time (h) 4.5  1.0 7.3  2.3 .001
ICU stay (d) 3.0  2.6 4.0  39 .22
Hospital stay (d) 9  7.6 10  17 .33
30-Day mortality (%) 1 3 .51
Myocardial infarction (%) 1 0 1.00
Gastrointestinal
complications (%)
11 7 1.00
Pulmonary complications (%) 8 11 .69
Graft infection (%) 5 0 .32
Wound complications (%) 19 26 .19
Fasciotomy (%) 1 44 .001
D-AFB, Dacron aortofemoral bypass; V-AFB, vein aortofemoral bypass.
JOURNAL OF VASCULAR SURGERY
July 200420 Jackson et alventional standard of a Dacron prosthetic graft. In light of
the good results reported with SFP vein for aortic recon-
struction to treat prosthetic infection, and the relatively
poor patency rates with conventional D-AFB in young
patients, the findings of our study should not be surprising.
Valentine et al1 in 1995 reported in a study of 73 patients
aged 50 years and younger undergoing AFB that 54% of
women and 47% of men had limb occlusion at 31 months.
More recently Reed et al3 reported on the influence of
patient age in patients undergoing AFB, and also observed
lower patency rates in younger patients. At 5 years, patients
younger than 50 years had a primary patency rate of 66%,
those aged 50 to 59 years had 87% patency, and those 60
years and older had a primary patency rate of 96%, more
similar to that generally reported for AFB overall.
The improved patency with SFP vein grafts is most
likely due to the inherent resistance to thrombosis generally
observed with vein grafts in general compared with pros-
thetic grafts. The decreased thrombogenicity of vein grafts
is particularly advantageous when dealing with reconstruc-
tion to smaller arteries, such as infrainguinal and coronary
procedures. Because younger patients tend to have smaller
aortic diameter,1,3 perhaps these younger patients also have
smaller caliber runoff arteries. Conversely, use of the more
thrombogenic prosthetic grafts with smaller runoff arterial
beds could be expected to result in lower patency rates
compared with vein grafts. The greater saphenous vein is
more readily harvested and prepared for use as a graft;
however, its use for aortoiliac or aortofemoral reconstruc-
tions has been tempered by poor patency. Saphenous vein
grafts in aortic reconstructions are prone to failure from
diffuse neointimal hyperplasia.6,7 Kinking of small-caliber
grafts and difficulty achieving a size match for the proximal
aortic anastomosis when using saphenous vein are addi-
tional difficulties associated with these grafts.
The main disadvantages of the V-AFB technique com-
pared with standard D-AFB are the significant morbidity of
fasciotomy and the increased complexity and duration of
operation. We have found that the presence of lower ex-
tremity ischemia is a risk factor for requiring fasciotomy
after V-AFB when performed for any indication, including
prosthetic aortic infection.8 Clearly, the group of patients
Table IV. Primary patency
Month Group
Patency
(%) SE
No.
left
12 D-AFB 88 0.05 32
V-AFB 100 0.00 13
24 D-AFB 75 0.07 22
V-AFB 100 0.00 11
36 D-AFB 67 0.08 16
V-AFB 100 0.00 4
48 D-AFB 67 0.08 13
V-AFB 100 0.00 4
60 D-AFB 56 0.10 9
V-AFB 100 0.00 3
D-AFB, Dacron aortofemoral bypass; V-AFB, vein aortofemoral bypass.in this report all have lower extremity ischemia, in distinc-
tion to prosthetic infection alone, and are thereby at in-
creased risk for compartment syndrome with this proce-
dure. The harvest of the SFP vein alone typically does not
result in significant venous morbidity,9 but the combina-
tion of altered venous circulation with ischemia reperfu-
sion, as seen in patients operated on to treat ischemic
symptoms, is likely responsible for the compartment syn-
drome and need for fasciotomy with V-AFB.
The additional operative time and technical complexity
of SFP vein harvest are additional factors that have likely
diminished broader acceptance of this conduit for arterial
reconstructions. We have not generally recorded the addi-
tional time required for SFP vein harvest and graft prepa-
ration, but it is probably in the range of an additional two
and a half hours, and was generally performed by two or
more surgeons working simultaneously on both legs. Bilat-
eral SFP vein harvest is greatly facilitated with a two-team
approach. The technical features of SFP vein harvest that
increase the complexity of saphenous vein harvest are in-
creased depth of wound; multiple branches of the SFP vein
and their requirement for double ligation; difficulty in
exposing the popliteal portion of the vein, given the over-
lying arterial and nerve branches that must be preserved;
and the care required in lysing the valves for a nonreversed
graft configuration. The nonreversed configuration is par-
ticularly needed for end-to-end aortic anastomoses to
achieve a proper size match. The SFP vein valves are in valve
sinuses that are relatively thin-walled and at risk for venous
injury during valvulotomy. Eversion of the vein eliminates
this problem, but introduces another element of technical
complexity. These thin-walled segments at valve sinuses
sometimes require suture reinforcement if they appear “pa-
per thin.”
Duplex ultrasound scanning is useful for preoperative
vein mapping of the SFP vein. Duplex scans enable identi-
fication of occluded or duplicated segments of vein that
may not be suitable for grafting. We have not validated any
formal diameter requirement for these veins, but in the
absence of thrombotic occlusion or rare hypoplasia of the
SFP vein, most segments can be used for grafting. When
the SFP vein is used for occlusive disease, as in this study,
smaller caliber veins can generally be used for end-to-side
proximal aortic anastomosis rather than a more complex
pantaloon configuration of the vein graft (Fig 2). Typically
the SFP vein can be dilated an additional 2 to 4 mm with
gentle distention with heparinized saline solution, render-
ing an ample diameter graft from veins measuring 6 to 7
mm in diameter as mapped at duplex scanning.
Until 2003 there was no Current Procedural Terminol-
ogy (American Medical Association) code for SFP vein
harvest. Notwithstanding any potential advantages of SFP
vein as a graft choice, significantly increased operative time
without reimbursement will not hasten its use. The 2003
Current Procedural Terminology code for harvest of SFP
vein is 35572, which has a relative value unit of 9.89. This
compares to an relative value unit of 9.21 for harvest of a
for a
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(CPT 35500).
Another issue that will certainly temper enthusiasm for
broader acceptance of this technique is its increased tech-
nical difficulty compared with standard Dacron grafting.
The V-AFB procedure took almost twice as long to per-
form, and this was in a center where there is significant
experience with use of the SFP vein for vascular grafts. The
procedures were performed in a tertiary care medical center
with training programs in general surgery and vascular
surgery, which provides additional resident and attending
surgeons for two-teaming the vein harvests and wound
closures. In a setting where a single surgeon must perform
the entire operation, the V-AFB procedure has obvious
drawbacks.
Although the slight survival advantage with D-AFB was
not significant, we would attribute any such difference to
the differences in the two patient populations. There were
more patients with diabetes in the V-AFB group, and more
patients with critical ischemia, reflecting a patient popula-
tion with more advanced atherosclerosis. Any survival dif-
ference between groups is more likely a reflection of this
increased prevalence of more advanced atherosclerosis in
the V-AFB group than it is attributable to the differences in
the two operative approaches. This is supported by the
similar 30-day mortality in the two groups.
We continue to use endovascular techniques for focal
aortoiliac occlusive disease, and have reported an early
experience with an aggressive endovascular approach in the
treatment of complex lesions (TransAtlantic Inter-Society
Fig 3. Life table graph of primary patency ratesConsensus document [TASC] C and D)10 with endolumi-
nal grafts.11 Despite the growing enthusiasm for endovas-
cular treatment of aortoiliac occlusive disease, in younger
patients the results are not so durable. Levy et al12 analyzed
the results of percutaneous transluminal angioplasty (PTA)
in patients younger than 45 years. The study evaluated 32
patients undergoing 53 PTA procedures for treatment of
46 legs with ischemia. PTA was performed in 28 iliac
arteries. Of these, 27% experienced no hemodynamic im-
provement, and the 3-year primary patency rate was only
66%. Eight patients required secondary procedures within
1 year of iliac PTA. Siskin et al13 recently reported a 65%
3-year primary patency rate with iliac artery stents in 42
patients younger than 50 years.
There are a number of limitations to our study. Because
the patients were not entered prospectively in a treatment
randomization protocol, it is not possible to conclude that
V-AFB is superior overall to D-AFB, despite the observed
patency advantages. Although aortic diameter was not re-
corded or measured routinely during angiography in these
patients, it is certainly possible that this entered the deci-
sion-making process of the attending surgeon when V-AFB
was offered to the patient. Small aortic diameter is a factor
that influences lower patency in young patients undergoing
AFB.1,3 An additional limitation is the lack of TASC criteria
scoring of the severity of aortoiliac occlusive disease. Pre-
operative ankle-brachial index and clinical indication (clau-
dication vs critical ischemia) are included and provide the
reader some means to compare the two groups. Another
limitation is the relatively short follow-up in both treatment
ortofemoral bypass with vein and with Dacron.
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sibly lost to follow-up after 1 year. Clearly, longer fol-
low-up will be necessary to confirm the findings of this
report, particularly those relating to patency rates.
On the basis of these results, we recommend that use of
SFP vein grafts be considered in younger patients (55
years) requiring AFB because of aortoiliac occlusive disease.
Despite the increased time and complexity of the procedure
and the frequent need for lower extremity fasciotomy, the
excellent graft patency rate and avoidance of prosthetic infec-
tion make V-AFB an attractive alternative to D-AFB in young
patients. We hope that the information presented here will
encourage greater acceptance of the use of V-AFB in these
patients. Additional experience with this technique in other
centers and extended follow-up of our patients will help define
the role of this procedure in this complex group of patients.
REFERENCES
1. Valentine RJ, Hansen ME, Myers SI, Chervu A, Clagett GP. The
influence of sex and aortic size on late patency after aortofemoral
revascularization in young adults. J Vasc Surg 1995;21:296-305.
2. Gagne PJ, Vitti MJ, Fink LM, Duncan J, Nix ML, Barnes RW, et al.
Young women with advanced aortoiliac occlusive disease: new insights.
Ann Vasc Surg 1996;10:546-57.
3. Reed AB, Conte MS, Donaldson MC, Mannick JA, Whittemore AD,
Belkin M. The impact of patient age and aortic size on the results of
aortobifemoral bypass grafting. J Vasc Surg 2003;37:1219-25.4. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral
reconstruction from superficial femoral-popliteal veins: feasibility and
durability. J Vasc Surg 1997;25:255-66.
5. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
6. Clagett GP, Bowers BL, Lopez-Viego MA, Rossi MB, Valentine RJ,
Myers SI, et al. Creation of a neo-aortoiliac system from lower extremity
deep and superficial veins. Ann Surg 1993;218:239-49.
7. Seeger JM, Wheeler JR, Gregory RT, Snyder SO, Gayle RG. Autoge-
nous graft replacement of infected prosthetic grafts in the femoral
position. Surgery 1983;93:39-44.
8. Modrall JG, Sadjadi J, Ali AT, Anthony T, Welborn MB, III, Valentine
RJ, et al. Deep vein harvest: predicting the need for fasciotomy. J Vasc
Surg 2004;39:387-94.
9. Wells JK, Hagino RT, Bargmann KM, Jackson MR, Valentine RJ,
Kakish HB, et al. Venous morbidity after superficial femoral-popliteal
vein harvest. J Vasc Surg 1998;29:282-91.
10. TransAtlantic Inter-Society Consensus (TASC). Management of pe-
ripheral arterial disease (PAD). J Vasc Surg 2000;31(suppl):S54-134.
11. Ali AT, Modrall JG, Lopez J, Brawley JG, Welborn MB, Clagett GP, et
al. Emerging role of endovascular grafts in complex aortoiliac occlusive
disease. J Vasc Surg 2003;38:486-91.
12. Levy PJ, Close T, Hornung CA, Haynes JL, Rush DS. Percutaneous
transluminal angioplasty in adults less than 45 years of age with prema-
ture lower extremity atherosclerosis. Ann Vasc Surg 1995;9:471-9.
13. Siskin GP, Englander M, Roddy S, Dowling K, Dolen EG, Quarfordt S,
et al. Results of iliac artery stent placement in patients younger than 50
years of age. J Vasc Intervent Radiol 2002;13:785-90.
Submitted Jan 20, 2004; accepted Apr 1, 2004.
Available online May 24, 2004.DISCUSSIONDr Robert B. Smith III (Atlanta, Ga). I wish to express
appreciation to the authors, who extended themselves in the search
for improved long-term results for their patients over a number of
short-term obstacles, including certain technical difficulties that
they readily acknowledge. They were willing to invest the necessary
additional time and effort in the operating room in an era when the
trend is in the opposite direction, toward quicker and less invasive
surgical procedures, wherein success is judged too often in terms of
months rather than years.
In all fairness and despite their conclusions, I doubt the
authors have won many converts here today. To tell the truth, I
haven’t found standard aortobifemoral bypass using Dacron to be
all that inferior for younger patients in my personal experience, but
must admit that it is becoming an operation on the verge of
extinction as endovascular methods gain in favor. In fact, program
directors must exercise care that they don’t produce a generation
of trainees inadequately skilled in certain basic open operations.
I have several questions for the authors:
1. Since this was not a randomized, prospective study, can you
assure us that the operations in both groups were performed by
the same mix of senior surgeons, or is it possible that you have
compared Dr. Clagett’s vein bypass cases with Dacron bypasses
done by residents functioning as the primary surgeon?
2. I guess we are all concerned about the frequent need for
fasciotomies in the vein group, not an inconsequential problem
for those patients. Was the need for fasciotomy related to the
frequency of critical ischemia, or is it an inherent risk of major
vein harvest? Was it done prophylactically at the time of the
initial operation or later, and how many patients required skin
grafts for closure?
3. Finally, in the 5% of Dacron patients who developed graft
infections, did you convert them to vein bypasses or simplyremove the graft and allow the patients to resume their previous
claudication status?
Dr Ahsan T. Ali. To answer the first question, yes, the same
group of surgeons who performed the Dacron performed the vein
bypass. It is one group out of Dallas, and they all performed either
the Dacron or the superficial vein bypass. The criteria were younger
patient, good operative risk, and smaller aortas. It was not random-
ized; I admit that.
Your second question regarding fasciotomies, it has an inher-
ent risk, and it was presented by this group last year at the national
meeting. When you have severe ischemia, especially an ABI of less
than 0.4, combined with venous hypertension, when you reperfuse
this ABI of 0.4 and you raise it, especially if the superficial femoral
artery is open and the profunda is also open, you raise it signifi-
cantly, there is a chance of reperfusion injury with venous hyper-
tension. Most of these, 90%, were prophylactic fasciotomies, and,
yes, they were performed at the end of the operation.
As far as skin graft, I can’t quote an exact number, but the
majority of these patients, and I would say about 60%, but I’d have
to look at it, had their primary fasciotomy sites closed in 5 to 7 days.
It is the initial edema, and once that goes down they are closed
primarily. Some had split-thickness skin grafts also.
Dr Francis Robicsek (Charlotte, NC). How can you propa-
gate the procedure or recommend a procedure that requires fas-
ciotomy in 44% of the cases? Why do you have such a high
occlusion rate in the Dacron graft group? Fifty-four percent in
young people? I think this number should be around 5% to 10%.
Dr Ali. This is for a selective group of patients. I think
fasciotomy is a morbidity, but you pay a price upfront, and these
patients have 100% primary patency.
As far as your second question is concerned, that is reported in
the literature. It is not only our group in which Dacron had poor
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know why they had that; I can’t specifically answer that.
Dr James Seeger (Gainesville, Fla). If you look at your data
and the other reported data, about half of these patients benefit
from having an SFV ABF and half of them don’t, because only half
the Dacron grafts fail at 5 years. So do you have a way of picking
out the ones we ought to be doing this more extensive procedure
in, or alternatively picking out the ones, the young patients, who
will tolerate a standard procedure?
Dr Ali. I would say I don’t know the answer to that exactly,
but somebody who is less than 50 years old with small aortic size
and critical ischemia who is a good operative risk and not morbidly
obese, I think those are the patients who benefit from this, because
the secondary interventions on these vein grafts are almost nonex-
istent. There were five patients who had subsequent distal bypassesdone, but these patients lived their lives without intervention, and
the grafts not getting any stenosis or occlusion. I don’t know the
exact answer of how those patients. . .I think that is maybe C-re-
active protein or something.
Dr Thomas Huber (Gainesville, Fla). Given this high-risk
patient population, what is your first choice of operation? Do you
do a Dacron bypass or do you go to the SFV bypass first?
Dr Ali. We still do the Dacron bypass in a good-risk patient
who is 55 or older or has a good sized aorta that is 20 mm, or more
than a 19-mm diameter. Again, this is a highly selected group of
patients. We do go to an endovascular approach if that is feasible.
If not, then we do offer both the vein graft and the Dacron graft to
the patients. Surprisingly, the patients want their own tissue. They
insist on the vein graft even though it is associated with high
morbidity.CORRECTIONS
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